DrugPatentWatch Database Preview
Drugs in Development Information for Ipatasertib
» See Plans and Pricing
What is the drug development status for Ipatasertib?
Ipatasertib is an investigational drug.
There have been 34 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and SOLTI Breast Cancer Research Group.
There are twenty-six US patents protecting this investigational drug and four hundred and forty-four international patents.
Summary for Ipatasertib
| US Patents | 26 |
| International Patents | 444 |
| US Patent Applications | 52 |
| WIPO Patent Applications | 413 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-12-01) |
| Vendors | 47 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response | Genentech, Inc. | Phase 2 |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | Hoffmann-La Roche | Phase 3 |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor | Canadian Cancer Trials Group | Phase 3 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | Start Trial | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Processes for the preparation of pyrimidinylcyclopentane compounds | GENENTECH, INC. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (South San Francisco, CA) F. HOFFMANN-LA ROCHE AG (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | European Patent Office | EP3119395 | 2034-03-17 | Start Trial |
| Ipatasertib | World Intellectual Property Organization (WIPO) | WO2015142605 | 2034-03-17 | Start Trial |
| Ipatasertib | Australia | AU2012236135 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | AU2012236138 | 2031-04-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
